By Farhad Ravandi, Francis Giles (auth.), Judith E. Karp MD (eds.)
Acute Myelogenous Leukemia is a well timed compilation of recent recommendations within the molecular pathogenesis and molecular remedy of acute myelogenous leukemia (AML). the point of interest is on chosen serious molecular determinants of AML pathogenesis and pathophysiology and the exploitation of those components via assorted healing brokers and modalities. Bringing jointly new thoughts and findings within the easy and scientific technological know-how of AML, the ebook emphasizes the molecular foundation for brand new treatments that stand to have the best capability effect at the scientific face of those ailments. The textual content offers insights into chosen novel ideas at the moment and prospectively being built, together with interruption of particular sign transduction pathways, modulation of gene expression, makes an attempt to reinstate differentiation, and immunomodulation. there's an emphasis all through at the bidirectional circulate of information among the medical and laboratory arenas, and either easy and medical scientists will make the most of this translational textual content.
Read or Download Acute Myelogenous Leukemia PDF
Similar nonfiction_9 books
Mammalian oocytes occupy a serious nexus in replica as they not just give a contribution part the genetic make-up of the embryo but additionally offer nearly the entire cytoplasmic development blocks required for maintaining embryogenesis. the adventure that transforms a primordial germ mobilephone right into a mature oocyte (or egg) able to fertilisation and embryonic improvement is of unrivalled complexity.
- Diabetes Care for the Older Patient: A Practical Handbook
- Avian Migration
- Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions
- Diagnostic Interviewing: Fourth Edition
Extra resources for Acute Myelogenous Leukemia
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-2245. Hussong JW, Rodgers GM, Shami PI. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000;95:309-313. Giles F1. Novel agents for the therapy of acute leukemia. CUIT Opin Oncol 2002;14:3-9. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential l-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Morgan MA, Dolp 0, Reuter CWO Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1I2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood 2001;97:1823-1834. 188. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J Bioi Chern 1995;270:27,489-27,494. 189. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR.
Mice with reduced GATA-I expression specifically in megakaryocytes, resulting from deletion of a gene-regulatory DNaseI hypersensitivity site, are thrombocytopenic but not anemic (150). The large majority of transient myeloproliferative disease (TMD) or acute megakaryocytic leukemias (AMKLs) that develop in Down syndrome patients carry mutations in intron 1 or exon 2 of the X-linked GATA-I gene (151). Similar to N-terminal CEBPA mutations, these alterations lead to translation from an internal ATG, corresponding to amino acid 84 of the long isoform.
Acute Myelogenous Leukemia by Farhad Ravandi, Francis Giles (auth.), Judith E. Karp MD (eds.)